Biogen Message Board - Msg: 10134944

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 156.28

+0.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Walkingshadow who wrote (1035)	6/15/1999 11:44:00 PM
From: synchro	Read Replies (1) of 1686

Biogen has one drug on the market with good earnings growth potential. Whether you think the valuation of Biogen as of now is another question. What is without a doubt is that Biogen is now funding its own research and development with operating cash flow instead of shareholder capital infusion. That makes a big difference in any decision to invest long-term. Why was Biogen's pipeline poor? Simple, Biogen as a previously small biotech "bet the farm" to bring the MS drug to market. Now they succeeded, naturally they can afford to turn attention to other drugs. Investing in biotech is like watching grass grow most of the time. A lot of times the grass just wither and die under the blazing sun, but occasionally the grass can sprout into something monstruously wonderful.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next